PIK3CA and neoplasm: In the joint analysis of these two studies, the addition of everolimus provided a statistically significant PFS benefit in patients with PIK3CA tumor mutations in the ER- subgroup (hazard ratio = 0.43; 95% CI, 0.22–0.86), with a lower effect in the ER+ subgroup (hazard ratio = 0.93; 95% CI, 0.55–1.57).